Metalloproteinase binding proteins: WO2009097397

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 8, 2010, Pages 1091-1095

  Itoh, Yoshifumi ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antibody; MMP; MT1 MMP; Phage display

Indexed keywords

MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; ANTIBODY; ANTINEOPLASTIC AGENT; MATRIX METALLOPROTEINASE INHIBITOR; PROTEINASE INHIBITOR;

BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL INVASION; DRUG MECHANISM; ENZYME BINDING; ENZYME INHIBITION; FIBROSARCOMA; HUMAN; MELANOMA; NONHUMAN; PROSTATE CANCER; REVIEW; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; METABOLISM; MOUSE; NEOPLASMS, EXPERIMENTAL; PATENT; PATHOLOGY; TUMOR VOLUME;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; METALLOENDOPEPTIDASES; MICE; NEOPLASMS, EXPERIMENTAL; PATENTS AS TOPIC; PROTEASE INHIBITORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954897099     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.488221     Document Type: Review

References (35)

1. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3(3):207-214
2. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92(8):827-839
3. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008;29(5):290-308
4. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19(56):6642-6650
5. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295(5564):2387-2392
6. Stocker W, Grams F, Baumann U, et al. The metzincins-topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci 1995;4(5):823
7. Overall CM, Kleifeld O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6(3):227-239
8. Itoh Y, Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 2006;206(1):1-8
9. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-65
10. Itoh Y. MT1-MMP: a key regulator of cell migration in tissue. IUBMB Life 2006;58(10):589-596
11. Yoshizaki T, Sato H, Maruyama Y, et al. Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma. Cancer 1997;79(1):139-144
12. Strongin AY, Collier I, Bannikov G, et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995;270(10):5331-5338
13. Belien AT, Paganetti PA, Schwab ME. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol 1999;144(2):373-384
14. Nagakawa O, Murakami K, Yamaura T, et al. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 2000;155(2):173-179
15. Seiki M, Yana I. Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci 2003;94(7):569-574 (Pubitemid 36975009)
16. Hiraoka N, Allen E, Apel IJ, et al. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998;95(3):365-377
17. Zhang W, Matrisian LM, Holmbeck K, et al. Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 2006;6:52
18. Hotary KB, Allen ED, Brooks PC, et al. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003;114(1):33-45
19. Miller MC, Manning HB, Jain A, et al. Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis. Arthritis Rheum 2009;60(3):686-697
20. Filippov S, Koenig GC, Chun TH, et al. MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. J Exp Med 2005;202(5):663-671
21. Hudson PJ, Souriau C. Recombinant antibodies for cancer diagnosis and therapy. Expert Opin Biol Ther 2001;1(5):845-855
22. Chun TH, Sabeh F, Ota I, et al. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J Cell Biol 2004;167(4):757-767
23. Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009;69(4):1517-1526
24. Jungel A, Ospelt C, Lesch M, et al. Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis. Ann Rheum Dis 2010;69(5):898-902
25. Monovich LG, Tommasi RA, Fujimoto RA, et al. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13. J Med Chem 2009;52(11):3523-3538
26. Piecha D, Weik J, Kheil H, et al. Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants. Inflamm Res 2010;59(5):379-389
27. Wu J, Rush TS, Hotchandani R, et al. Identification of potent and selective MMP-13 inhibitors. Bioorg Med Chem Lett 2005;15(18):4105-4109
28. Anilkumar N, Uekita T, Couchman JR, et al. Palmitoylation at Cys574 is essential for MT1-MMP to promote cell migration. FASEB J 2005;19(10):1326-1328
29. Uekita T, Itoh Y, Yana I, et al. Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity. J Cell Biol 2001;155(7):1345-1356
30. Jiang A, Lehti K, Wang X, et al. Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc Natl Acad Sci USA 2001;98(24):13693-13698
31. Remacle A, Murphy G, Roghi C. Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. J Cell Sci 2003;116(Pt 19):3905-3916
32. Holmbeck K, Bianco P, Caterina J, et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999;99(1):81-92
33. Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 2000;97(8):4052-4057
34. Oblander SA, Zhou Z, Galvez BG, et al. Distinctive functions of membrane type 1 matrix-metalloprotease (MT1-MMP or MMP-14) in lung and submandibular gland development are independent of its role in pro-MMP-2 activation. Dev Biol 2005;277(1):255-269
35. Okada A, Tomasetto C, Lutz Y, et al. Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A. J Cell Biol 1997;137(1):67-77